Abstract disclosures for ASCO 2009

[Guest guest]

Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of

cytogenetic response and progression-free survival (PFS).

http://www.abstract.asco.org/AbstView_65_33899.html

********************************

Omacetaxine in T315I CML Pts results in de-selection of the T315I clone and

induces hematologic

and cytogenetic responses.

http://www.abstract.asco.org/abst_files/hp356s_381s_leukemia.PDF

*************************************

The combination of imatinib with nilotinib or HHT

showed strong synergy, overcoming BCR-ABL135INS-induced resistance in

vitro. Conclusions: These findings emphasize the importance of the overlooked

alternatively spliced BCR-ABL135INS protein and may provide a

strategy to treat resistant disease and eradicate residual CML.

http://www.abstract.asco.org/abst_files/hp356s_381s_leukemia.PDF

More free information (LOL)

Lottie